A July 2026 Gallup poll finds 11% of American adults now take a GLP-1 for weight loss, up from 3% in 2024 — while the national obesity rate has dropped to its lowest point since 2022.
CMS launched the Medicare GLP-1 Bridge on July 1, 2026 — a $50/month copay demonstration covering Wegovy, Zepbound, and Foundayo through 2027. Here’s exactly who qualifies and what’s actually covered.
GHK-Cu, PTD-DBM, and topical peptide combinations are being studied for hair loss. Here’s what the published research shows and where the evidence gets thin.
Side effect profiles for research peptides range from well-characterized to purely anecdotal. Here’s a research-graded breakdown of what’s actually documented vs what comes from community reports.
Cold exposure, time-restricted eating, zone 2 training, and peptide compounds — a research-backed breakdown of the most-studied metabolic biohacking approaches and what the evidence actually supports.
Joint and connective tissue research is one of the most active areas in peptide science. Here’s what BPC-157, TB-500, and collagen peptides show in published research for musculoskeletal applications.
Beyond weight on a scale — GLP-1 research tracks fat mass, lean mass, bone density, and metabolic markers. Here’s what the clinical trial data shows about body composition.
Research peptides exist in a complex regulatory space. This is an educational overview of the legal framework in the US, the “research use only” designation, and what that actually means.
NMN and NR are two of the most popular longevity supplements. Here’s a rigorous breakdown of the NAD+ biology, what clinical trials have shown, and where the hype exceeds the evidence.
Retatrutide activates three receptors simultaneously — GLP-1, GIP, and glucagon. Phase 2 data shows remarkable weight outcomes. Here’s what the research shows about the next frontier in incretin pharmacology.
